$400,000 Reorder Highlights HYLA’s Accelerating Product Demand
CAVE CREEK, AZ, Oct. 12, 2023 (GLOBE NEWSWIRE) — via NewMediaWire – Endexx® Corporation (OTCQB: EDXC), a provider of innovative plant-based wellness and nutritional products, today announced it has secured a reorder for its non-nicotine based vape product, HYLA, from its distributor in Italy.
This $400,000 reorder represents a mix of the current DOPA 1200 puff device and the new 4500 puff device. The new 4500 device is awaiting final permit for Italy and will be shipped in our First Fiscal Quarter 2024. The reorder marks the strengthening of our relationships with our distributors and continues to show accelerated demand for HYLA products worldwide.
“For HYLA, securing this reorder in Italy not only underscores the demand for non-nicotine vape products, but also reaffirms the strength and vitality of our distribution relationships,” said Todd Davis, CEO of Endexx Corporation. “As we continue to navigate the global marketplace, it’s evident that our leadership in “Science and Compliance©” resonates deeply with our international partners and consumers.”
For questions, information, or to set up a meeting with management, please contact IR@Endexx.com
www.endexx.com & www.cbdunlimited.com
About Endexx Corporation
Endexx Corporation develops and distributes all natural, plant-derived wellness products and topical skincare products. Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness. The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health. www.endexx.com
Hyla currently markets its proprietary non-nicotine, guarana and L-Dopa-based vape products in a wide variety of flavors. The Hyla device is the first non-nicotine vape product to be produced in this manner in the United States and provides an unprecedented 4,500 puffs per device. Hyla is currently being distributed in 10 countries and has signed distribution agreements with an additional nine countries. www.tryhyla.com
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995
This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.
No Offer or Solicitation. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and, where applicable, the requirements under the securities laws of any other applicable jurisdiction.
For further information, please contact:
Endexx Corporation
IR@Endexx.com
480-595-6900
